Efficacy and Safety of Chiglitazar Added to Glargine in Patients With Type 2 Diabetes

Inclusion Criteria: * 1.In accordance with the World Health Organization (WHO) issued in 1999 diabetes diagnostic criteriaType 2 diabetes mellitus (T2DM); * 2\. Male or female patients ≥18 years old; * 3, BMI≥18.5 Kg/m2, \< 35 Kg/m2; * 4, Glycosylated hemoglobin (HbA1C) \> 7.5%; ≤10.5%; * 5, Stable dose (insulin daily therapeutic dose change within ±20%) of glycerine or DI The therapeutic dose of Terterigu or NPH basal insulin is ≥0.25IU/kg/ day/or 20IU/ day； * 6, Stable basic insulin treatment combined with metformin (metformin dose ≥1000mg/Days or maximum tolerated dose) ≥3 months； * 7\. Voluntarily sign informed consent and agree to be randomly assigned to any experimental group. Exclusion Criteria: * 1, Type 1 diabetes or specific type diabetes; * 2\. Fasting blood glucose (FPG) exceeding 13.3 mmol/L (240 mg/dL); * 3, refractory hypertension \[that is, on the basis of improving lifestyle, the application of a reasonable and tolerable sufficient amount of 3 or more antihypertensive drugs (including diuretics) for more than 1 month still does not reach the standard, or take 4 or more antihypertensive drugs to effectively control blood pressure\]; * 4\. Triglyceride (TG) \> 500 mg /dL (5.65 mmol/L); * 5, is taking or in the last 1 month has taken fibrate drug treatment; * 6, lower limb edema or general edema; * 7\. Experienced 3 or more episodes of severe hypoglycemia and/or unintentional hypoglycemia in the 6 months prior to screening; * 8\. A definite diagnosis of osteoporosis or any other known bone disease; * 9\. History of diabetic ketoacidosis, diabetic hyperglycemia hyperosmolar syndrome, lactic acidosis and other acute complications of diabetes; * 10\. Severe microvascular complications (proliferative retinopathy; Urinary albumin/creatinine ratio \&gt; 300 mg/g; Marked peripheral neuropathy, etc.); * 11\. Large vascular lesions leading to hospital admission within 6 months before inclusion; * 12, The New York Heart Association (NYHA) defines congestive heart failure as grade III or IV * 13, significant liver and kidney dysfunction and systemic disease (significant liver dysfunction is defined as AST\&gt; 2.5 times the upper limit of normal and/or ALT\&gt; 2.5 times the upper limit of normal and/or total bilirubin \&gt; 1.5 times the upper limit of normal value; Renal dysfunction was defined as moderate to severe renal insufficiency (eGFR\&lt;60 ml/ (min\*1.73m2)). * 14\. Use of other hypoglycemic agents not specified in the inclusion criteria (thiazolidinediones, GLP-1RA, premixed or fast-acting insulin) in the current or 3 months prior to screening, with the exception of short-term treatment with additional insulin (a total of 7 days or less) for complications; * 15, pregnant or lactating women, women of childbearing age who are unable or unwilling to take adequate contraception; * 16\. Participating in clinical trials of other drugs or medical devices during or within 3 months prior to screening; * 17\. The investigator considers it inappropriate to participate in this clinical trial.